« Previous
Next »
International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2
, Pages 297-303
, 1 June 2002
Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer
References
-
Prostate.
In:
Fleming I, Cooper J, Henson D, et al. editor. AJCC cancer staging manual. Philadelphia: Lippincott-Raven; 1997;p. 219–224
- Outcome evaluation of the 1997 AJCC staging system for prostate carcinoma treated by radiation therapy. Cancer. 1999;85:1816–1821
- Defining the appropriate radiation dose for pretreatment PSA ≤10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:649–654
-
.
ICRU Report No. 50. Prescribing Recording, and Reporting Photon Beam Therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993;
- Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
-
.
Nonparametric estimation from incomplete observations.
J Am Stat Assoc. 1958;53:447–457
- . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
-
.
The statistical analysis of failure time data. New York: John Wiley & Sons; 1980;
- Validating a treatment policy for PSA failures following 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:206
- The durability of external beam radiation therapy for prostate cancer (Can it be identified?). J Urol. 1999;162:758–761
- Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 1999;161:1199–1205
- Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol. 1998;160:86–90
- The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome assessed systematic biopsy and serum prostate specific antigen. Cancer. 1997;79:81–89
- Prostate-specific antigen doubling times in patients with prostate cancer (A potentially useful reflection of tumor doubling time). Int J Radiat Oncol Biol Phys. 1993;27:125–127
- . Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638–2643
- Pretreatment prostate specific doubling times (Clinical utility of this predictor of prostate cancer behavior). Int J Radiat Oncol Biol Phys. 1996;34:549–553
- Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–917
PII: S0360-3016(02)02717-7
© 2002 Elsevier Science Inc. All rights reserved.
« Previous
Next »
International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2
, Pages 297-303
, 1 June 2002
